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IL interleukin
IκB inhibitor of NF-κB
MAb monoclonal antibody
MET mesenchymal-epithelial transition factor
MCP monocyte chemotactic protein
MIP macrophage inflammatory protein
MMP matrix metalloproteinase
MT-MMP membrane type matrix metalloproteinase
NF-κB  nuclear factor-κB
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PG (D, E, F) prostaglandin (D, E, F)
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RPMI Roswell Park Memorial Institute (medium)
SDF stromal-derived factor
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM standard error of the mean
TNF-α	 tumor necrosis factor-α 
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VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
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Abstract
Wound healing is a complex process that requires an interplay between sev-
eral cell types. Classically, fibroblasts have been viewed as producers of extracel-
lular matrix, but more recently they have been recognized as orchestrators of the 
healing response, promoting and directing inflammation and neovascularization 
processes. Compared to those from healthy tissue, inflammation-associated fibro-
blasts display a dramatically altered phenotype and have been described as sen-
tinel cells, able to switch to an immunoregulatory profile on cue. However, the 
activation mechanism still remains largely uncharacterized. 
Nemosis is a model for stromal fibroblast activation. When normal human pri-
mary fibroblasts are deprived of growth support they cluster, forming multicellu-
lar spheroids. Clustering results in upregulation of proinflammatory markers such 
as cyclooxygenase-2 and secretion of prostaglandins, proteinases, cytokines, and 
growth factors. Fibroblasts in nemosis induce wound healing and tumorigenic re-
sponses in many cell types found in inflammatory and tumor microenvironments. 
This study investigated the effect of nemotic fibroblasts on two components of 
the vascular system, leukocytes and endothelium, and characterized the inflam-
mation-promoting responses that arose in these cell types. Fibroblasts in nemosis 
were found to secrete an array of chemotactic cytokines and attract leukocytes, as 
well as promote their adhesion to the endothelium. Nuclear factor-κB, the mas-
ter regulator of many inflammatory responses, is activated in nemotic fibroblasts. 
Nemotic fibroblasts are known to produce large amounts of hepatocyte growth 
factor, a motogenic and angiogenic factor. Also, as shown in this study, they pro-
duce vascular endothelial growth factor. These two factors induced migratory 
and sprouting responses in endothelial cells, both required for neovascularization. 
Nemotic fibroblasts also caused a decrease in the expression of adherens and tight 
junction components on the surface of endothelial cells.
The results allow the conclusion that fibroblasts in nemosis share many simi-
larities with inflammation-associated fibroblasts. Both inflammation and stromal 
fibroblasts are known to be involved in tumorigenesis and tumor progression. Ne-
mosis may be viewed as a model for stromal fibroblast activation, or it may cor-
relate with cell-cell interactions between adjacent fibroblasts in vivo. Nevertheless, 
due to nemosis-derived production of proinflammatory cytokines and growth fac-
tors, fibroblast nemosis may have therapeutic potential as an inducer of controlled 
tissue repair. Knowledge of stromal fibroblast activation gained through studies 
of nemosis could provide new strategies to control unwanted inflammation and 
tumor progression. 
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Review of the literature
The importance of wound care was known by healers in Ancient Egypt, accord-
ing to the first records, dating from 1400 BC. However, the concept of hemostasis 
was not understood, and bleeding was most likely only poorly controlled. The first 
written record regarding the importance of hemorrhage control dates back to 1500 
BC, and this papyrus from Egypt contains instructions on how to stop bleeding us-
ing heated instruments and fire. In Ancient Greece, bleeding was already controlled 
by mechanical means. From records that remain today it can be deduced that 
the Roman physician Cornelius Celsus was probably the first to mention the two 
hallmarks of wound care: treatment of hemorrhage and control of inflammation 
(Broughton et al., 2006). Sadly, most knowledge was lost or forgotten during the 
Middle Ages, and scientific interest in wound care, hemostasis, and inflammation 
was re-ignited again only approximately 500 years ago. Over the last century the 
links between cancer and inflammation have gradually become evident (reviewed 
in Balkwill and Mantovani, 2001). In addition, leukocyte-endothelial interactions 
(Cohnheim, 1867), angiogenesis (Lang, 2001), and the importance of fibroblasts in 
inflammation (Gabbiani et al., 1971; Smith et al., 1997) were discovered, ultimately 
resulting in the rapid accumulation of scientific information and care practices.
Early steps to acute inflammation: the interplay between leukocytes 
and endothelium
The process of wound repair is a tightly controlled process, which is required 
when tissue function is impaired by e.g. insult or infection (Li et al., 2007; Med-
zhitov, 2008). Acute inflammation has evolved to act as a driving force during the 
repair process. Wound healing has partially overlapping phases with clearly defined 
functions, beginning with the hemostasis response and ending in the resolution of 
inflammation, and healed tissue. In the case of tissue injury, the first occurrence is 
often vessel disruption, which results in a hemostasis response: bleeding, platelet 
aggregation, and finally clot formation. The first steps in the inflammation response 
begin already with the proteolytic cascades required for clot formation, but cells 
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present at the injury site must recognize the damage in order to alert the inflam-
matory defense system.
Activation of the endothelial surface leads to enhanced adhesion of leukocytes
One important cell type in the first line of defense is the endothelial cell, which 
lines blood vessel walls. In healthy tissue, the endothelium forms a semipermeable 
membrane that allows the exchange of small molecules and the entrance of a low 
amount of patrolling macrophages. A crucial component of inflammation is the 
extravasation of inflammatory leukocytes such as polymorphonuclear neutrophils 
and monocytes, which invade the inflamed tissue and surrounding stroma where 
they take part in host defense and tissue repair (Figure 1) (Chavakis et al., 2009; 
Granger and Kubes, 1994; Muller, 2009). The activation of monocytes to mac-
rophages is especially important for the inflammatory response, because an acti-
vated, tissue-resident macrophage not only clears tissue of pathogens and debris, 
but also takes part in controlling the inflammatory response by way of cytokine 
and growth factor secretion (Serbina et al., 2008). For these cells to recognize the 
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Figure 1. Schematic model of leukocyte-endothelial interactions on the vessel wall in healthy 
and inflamed vasculature, and the influence of the underlying stromal fibroblasts.
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site of extravasation, the endothelium must transmit distress signals, and thus be 
in an activated state.
Endothelial cells are anchored to a basement membrane and require constant 
contact with the extracellular matrix (ECM) for proper function. The endothelial 
cell is adaptive and responsive to its microenvironment: it displays various pheno-
types depending on the type of vasculature or the organ it resides in (Langenkamp 
and Molema, 2009; Pai and Ruoslahti, 2005). Activation of the endothelium causes 
the cells to shift phenotype or function (Zimmerman et al., 1999). The outcome 
is a dynamic process that is tailored to meet a specific need, related to the spe-
cific microenvironmental stimulus in question. Therefore, there is no single, spe-
cific characterization of the process of endothelial activation. Classical activating 
agents are thrombin, histamine, tumor necrosis factor-α (TNF-α), and various cy-
tokines, all of which result in slightly different profiles of activation. The response 
varies temporally and the first response is rapid. Some activation markers, such as 
platelet-selectin, are released from intracellular stores and upregulated in a matter 
of minutes (Hattori et al., 1989; Zimmerman et al., 1999). The proinflammatory 
transcription factor nuclear factor κB (NF-κB) is also often activated within min-
utes (Li, 2002; Sen and Baltimore, 1986). Other markers, such as the cell-surface 
deposition of intercellular adhesion molecule-1 (ICAM-1), require de novo protein 
synthesis and thus a time-span of several hours for proper activation (Dustin et 
al., 1986). Such temporal differences are important in orchestrating a controlled, 
sequential inflammatory response.
One purpose served by proinflammatory endothelial activation is to increase 
the adhesion of leukocytes, enabling their activation and subsequent extravasa-
tion into inflamed tissue (Chavakis et al., 2009; Granger and Kubes, 1994; Muller, 
2009). The major site for extravasation is the postcapillary venule, where lower 
shear stress results in enhanced interactions with the vessel wall (Granger and 
Kubes, 1994). The adhesion process for leukocytes is initiated with a weak adhesive 
interaction that causes the cell to roll over the endothelium and is followed by 
a firm, high-adhesive sticking to the vessel wall. Rolling is mediated by selectins 
(leukocyte-, endothelial- and platelet-selectins) and their glycoprotein ligands, and 
results in a reduction in the cell’s flow speed, allowing further, firmer adhesive in-
teractions to take place (Vestweber and Blanks, 1999). ICAM-1 on the endothelial 
cell, and its receptors on the leukocyte, the β2-integrins (CD11/CD18), are mol-
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ecules that mediate firm adhesion. ICAM-1 is a glycoprotein widely expressed on 
the endothelial cell surface in an active form, and its expression can be induced by 
stimuli such as exposure to cytokines (Dustin et al., 1986; Lawson and Wolf, 2009; 
Patarroyo et al., 1987). The β2-integrin group consists of various CD11 subunits 
bound to a common CD18 subunit (Gahmberg et al., 1997). When activated by the 
contact with the endothelium, the β2-integrin undergoes a conformational change 
resulting in a higher affinity for its ligand. Adhesion can be further augmented by 
membrane clustering of multiple active β2-integrin units (Gahmberg et al., 2009). 
As a result, the leukocyte adheres to the vessel wall, flattens, crawls to an appro-
priate area, and attempts to transmigrate through the endothelium into inflamed 
tissue (Muller, 2009).
Decreased barrier function of the endothelium aids leukocyte extravasation
For successful extravasation, leukocytes need to be allowed access through 
a monolayer of endothelial cells. Leukocytes use two pathways to transmigrate 
through the endothelial layer. The most studied pathway is the paracellular path-
way, where the leukocyte pushes through the endothelium between adjacent 
cells. Transmigration can also take place transcellularly, through the endothelial 
cell body, seemingly by utilizing vesicular vacuolar organelle structures (Feng et 
al., 1998; Garrido-Urbani et al., 2008), but this pathway seems to be less common 
(Carman and Springer, 2004). 
Extravasation requires the endothelium to increase its permeability around the 
site of injury (Aghajanian et al., 2008; Wallez and Huber, 2008). The physical bar-
rier function of the endothelium, including control of the flow of ions, macromol-
ecules, and blood cells, is regulated by tight junctions between endothelial cells 
(Bazzoni, 2006; Farquhar and Palade, 1963). The claudin family transmembrane 
proteins are the building blocks of tight junctions. They form strands by interacting 
both with each other on the same cell (heterophilic binding) as well as by binding 
two cells tightly together (homophilic binding) (Findley and Koval, 2009). Typically, 
each claudin-expressing tissue, such as epithelium and endothelium, harbors sev-
eral types of claudin, and the expression profile is tissue-specific. The importance of 
the endothelial cell-specific claudin-5 in regulating endothelial permeability is well 
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illustrated in blood-brain-barrier models, where claudin-5 deficiency causes im-
pairment of the blood-brain-barrier (Morita et al., 1999; Nitta et al., 2003). Clau-
dins are associated with ZO-1 (zonula occludens-1) on the cytosolic side (Fanning 
and Anderson, 2009; Itoh et al., 1999). ZO-1 is a scaffolding protein that binds a 
number of tight junction proteins and orchestrates the assembly of tight junctions 
into functional strands at cell-cell junctions (Umeda et al., 2006).
Endothelial tight junctions are spatially intermingled with adherens junctions, 
which control cell-cell adhesion of the monolayer, as well as with several signaling 
pathways regulating growth and differentiation (Dejana et al., 2008; Farquhar and 
Palade, 1963). There are several types of endothelial adherens junctions, and a ma-
jor type contains the transmembrane protein vascular endothelial (VE) cadherin. 
VE-cadherin junctions are believed to play a major role in stabilizing endothelial 
cell contacts and thus vascular integrity and physiological functions (Corada et al., 
1999; Lampugnani et al., 1992; Vestweber, 2008). VE-cadherin forms homophilic 
contacts on the cell surface, and adhesion is dependent on direct association with 
β-catenin on the intracellular side (Ozawa et al., 1989; Xu and Kimelman, 2007). 
Functioning as a scaffold protein, β-catenin links VE-cadherin to the actin cyto-
skeleton. ZO-1 is also known to interact with adherens junction proteins during the 
formation of junctional complexes, and may directly regulate activity of mature 
adherens junctions (Fanning and Anderson, 2009). VE-cadherin and β-catenin act 
together as gatekeepers for leukocyte transmigration, and have been shown to be 
transiently removed from cell-cell junctions at the site of transmigration (Allport 
et al., 2000).
Chemokines promote leukocyte chemotaxis
Cytokines are signaling molecules that mediate the messages in a complicated 
cross-talk between all cell types involved in the inflammatory response. For an ef-
fective inflammatory host response to take place, leukocytes must be directed to 
the site of injury. Extravasated and tissue-resident leukocytes are attracted by an 
increasing gradient of chemotactic cytokines or chemokines (Table 1, see following 
page). There are two major groups of chemokines: the CXC chemokines and the CC 
chemokines, named after differing peptide motifs in the respective proteins (Thor-
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pe et al., 2003). Chemokines both within and between groups share approximately 
20-50% homology on the amino acid level (Strieter, 2002). Their targets are dif-
ferent: the CXC chemokines, e.g. CXCL1, 2, 3 (growth-related oncogene (GRO) -α, 
-β, -γ), and CXCL8, are classically viewed as granulocyte and eosinophil specific, 
binding to the G-protein-coupled receptors CXCR1-6 on the target cells. The CC 
chemokines, e.g. CCL2 (monocyte chemoattractant protein-1; MCP-1), CCL3 (mac-
rophage inflammatory protein-1α; MIP-1α), and CCL5 (regulated upon activation, 
normal T cell expressed and secreted; RANTES), are mainly directed towards mono-
cyte-macrophages and lymphocytes, and bind to the receptors CCR1-11 on the leu-
kocyte (Rossi and Zlotnik, 2000; Sharma, 2010). Chemokines are secreted into the 
microenvironment, but they can also be presented on the surface of endothelial 
cells, in association with proteoglycans, causing rolling and adhering leukocytes to 
activate and prepare for battle (Rot and von Andrian, 2004; Tanaka et al., 1993).
   Main
Chemokine Alternative Main leukocyte
name name sources targets Receptors
CXCL1 GRO-α EC, FB, M N  CXCR1,2 
CXCL2 GRO-β EC, FB, M N CXCR2
CXCL3 GRO-γ EC, FB, M N CXCR2
CXCL8 IL-8 EC, FB, KC, M, N MP, N CXCR1,2
CCL2 MCP-1 M, EC, SMC M CCR2
CCL3 MIP-1-α L, M, MP M CCR1,5
CCL4 MIP-1-β L,  M, MP M CCR5
CCL5 RANTES FB, TL  B,  EO,M, TL CCR1,3,5
Table 1. Chemokines discussed in this study.
B (basophil), EC (endothelial cell), EO (eosinophil), FB (fibroblast), KC (keratinocyte), L (lym-
phocyte) M (monocyte) MP (macrophage), N (neutrophil), SMC (smooth muscle cell), TL (T-
lymphocyte)
(Thorpe et al., 2003; COPE: Horst Ibelgaufts’ Cytokines & Cells Online Pathfinder Encyclopae-
dia, www.copewithcytokines.org)
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The expression of many chemokines is regulated by the transcription factor NF-
κB, a key regulator of various pathogen-response and inflammation-related genes 
(Gilmore, 2006; Li, 2002; Sen and Baltimore, 1986). The NF-κB complex consists 
of two subunits, and these subunits are composed of combinations of p65 (RelA), 
p50/p105 (NF-κB1), p52/p100 (NF-κB2), c-Rel, or RelB. All proteins can form het-
erodimers, and all except RelB can form homodimers. Activated NF-κB consists 
mainly of p65 together with either p50 or p52. The NF-κB complex remains inac-
tive in the cytoplasm, bound to its endogenous inhibitor IκB (inhibitor of NF-κB). 
When activated upon various stimuli, either by the cell itself or by an external sig-
nal, IκB is ubiquitinated, which leads to release of NF-κB and rapid degradation of 
IκB in the proteasome. The liberated NF-κB translocates to the nucleus, where it 
binds to DNA and regulates the transcription of a plethora of target genes. Hence, 
NF-κB plays a pivotal role in triggering and maintaining inflammation, and it is 
often found to be constitutively active in inflammatory disorders (Hayden et al., 
2006).
Fibroblasts are modulators of the inflammation reaction
It is still a challenge to define exactly what a fibroblast is. It is of mesenchymal 
or neural crest origin, and usually recognized morphologically as an adherent, flat, 
spindle-shaped cell with a flat, oval nucleus. When examined histologically, the 
fibroblast lacks the endothelial cell marker CD34, the epithelial cell marker cytok-
eratin, and the hematopoietic cell marker CD45, but is often vimentin-positive. 
Yet, fibroblasts are by no means a single cell type, but display a heterogeneous 
phenotype that varies between organs and even within a single tissue. The fibro-
blast population in one organism is made up of various subsets of cells, each with 
distinct protein expression profiles and differing functions (Chang et al., 2002). 
Previously, it was thought that the sole function of a fibroblast was to produce 
and maintain the ECM, by which they are interconnected, producing components 
such as collagens and fibronectin. However, it has recently been appreciated that 
fibroblasts are also active initiators, controllers, and modulators of the inflamma-
tory defense response (Baglole et al., 2006; Flavell et al., 2008). The traditional 
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view of vascular inflammatory reactions has been that of an inside-out response, 
beginning with endothelial activation, leukocyte extravasation, and an inflamma-
tory response that spreads outwards from the vasculature. Recently, the opposite 
has been suggested: in the outside-in hypothesis, adventitial tissue, especially fibro-
blasts and leukocytes, are activated and influence vascular inflammation responses 
exogenously (Maiellaro and Taylor, 2007). Although further research is required to 
properly characterize this pathway, it presents an interesting perspective on the 
role of fibroblasts in triggering vascular inflammation responses.
Fibroblasts are tissue-resident sentinel cells
Unstimulated fibroblasts in healthy tissues produce a basal level of chemotactic 
cytokines such as CXCL8, CXCL12, CCL3, and CCL2, and the pattern of chemokines 
expressed varies with tissue type (Brouty-Boyé et al., 2000; Lukacs et al., 1994). 
Fibroblasts derived from inflammatory tissue have an altered chemokine profile 
(Hogaboam et al., 1998). Macrophages co-cultured with fibroblasts induce con-
tact-dependent expression of cytokines, especially CCL3 (Hogaboam et al., 1998). 
Therefore, it has been suggested that fibroblasts play a role as sentinel cells, capable 
of switching to a phenotype that actively promotes an inflammatory response by 
producing cytokines, growth factors, and proteases under conditions such as tissue 
repair after injury, fibrosis, pathological organ remodeling, and cancer (Orimo and 
Weinberg, 2006; Smith et al., 1997). Fibroblasts are also capable of dysregulating 
inflammation, as displayed by mice injected with fibroblasts lacking the inflamma-
tory regulator RelB. The result is a large local accumulation of inflammatory cells. 
RelB-/- fibroblasts were also shown to produce enhanced numbers of proinflamma-
tory chemokines (Xia et al., 1997). This study shows the importance of controlling 
the fibroblast-derived inflammatory response.
The role of fibroblasts as tissue-resident sentinel cells was first proposed by 
Smith et al. (Smith et al., 1997). They support this theory with four observations: 
firstly, fibroblasts form a heterogeneous population, and secondly, they display di-
verse phenotypes in different anatomical regions. Thirdly, fibroblasts are capable of 
activation, upon which chemokines are produced and released, and fourthly, such 
activated fibroblasts are capable of regulating and maintaining leukocyte infiltra-
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tion in damaged tissue. Thus, fibroblasts form an extended inflammatory defense 
system and act as an early warning system by secreting chemokines and other 
proinflammatory molecules that act in a paracrine fashion to alert the surrounding 
cells and tissues of immediate danger (Smith et al., 1997; Xia et al., 1997). 
Fibroblasts in many tissues express cyclooxygenase-1 (COX-1) and display basal 
levels of some of its end products, such as prostaglandin E2 (PGE2) (Wang et al., 
1996). Several types of fibroblasts, including those from lung, synovia, and orbita 
are known to also express the inducible COX-2 isoform upon stimulation (Crofford 
et al., 1994; Wang et al., 1996; Zhang et al., 1998). Like many cytokines, COX-2 is 
also upregulated by NF-κB (Newton et al., 1997), which enhances the gatekeeper 
role of the latter in orchestrating the inflammatory response. 
Stromal fibroblasts in inflammation: the myofibroblast phenotype
Gabbiani et al. discovered a type of fibroblast with a contractile function in 
healing wounds (Gabbiani et al., 1971; Gabbiani et al., 1978). This kind of fibroblast 
was further characterized by Sappino et al., who found similar, smooth muscle-like 
stromal cells expressing α-smooth muscle actin (α-SMA) in malignant breast tis-
sue (Sappino et al., 1988). Due to their muscle-like characteristics they were named 
“myofibroblasts”. In contrast to fibroblasts in normal adult tissues, myofibroblasts 
in healing wounds make direct cell-cell contacts, such as through adherens and gap 
junctions (Ehrlich and Diez, 2003; Gabbiani et al., 1978; Hinz and Gabbiani, 2003). 
Typically, myofibroblasts also display a secretory phenotype: they produce chemo-
kines and prostaglandins, and express both COX-1 and COX-2 isoforms (Powell et 
al., 1999). 
Differentiation towards the myofibroblast phenotype can be stimulated by 
various agents such as transforming growth factor-β, the ED-A splice variant of 
fibronectin, and changes in mechanical and tensile stress in the microenvironment 
(Hinz, 2007a; Serini et al., 1998; Tomasek et al., 2002). Fibroblast-to-myofibroblast 
differentiation in the wound-healing environment is a generally acknowledged 
phenomenon. While fibroblasts in various pathological tissue environments display 
some classical myofibroblast markers (e.g. α-SMA), they do not always express 
other such markers (e.g. fibronexi, gap junctions, prominent rough endoplasmic 
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reticulum). Also, other cell types have been shown to develop a spindle-shaped, 
α-SMA phenotype (Eyden, 2001). Due to these complications, the exact myofibro-
blast phenotype has not yet been clearly defined (Eyden, 2008). Currently, the pre-
cise origins of the myofibroblast are also not known. It is assumed that a common 
pathway for myofibroblast differentiation is from local, tissue-resident fibroblasts, 
but myofibroblasts may also arise from epithelial cells via epithelial-mesenchymal 
transition, or differentiate from pericytes, smooth-muscle cells, or circulating fi-
brocytes (Gabbiani, 2004; McAnulty, 2007). However, fibroblasts displaying myo-
fibroblast characteristics are abundant in inflammatory, fibrous, and malignant 
stroma (Hinz et al., 2007b; Powell et al., 1999). This highlights the importance of 
regarding fibroblasts as a heterogeneous group of cells with possibly slightly vary-
ing functions within the stroma.
Later stages in tissue repair: neovascularization of the stroma
The process of tissue repair requires intense proliferation of several cell types and 
construction of a temporary, stromal microenvironment to support the healing pro-
cess. Activated fibroblasts gather in and around the injured site, and together with 
inflammatory blood cells they form granulation tissue, which serves as a scaffold 
for the restoration of functional, healthy tissue. Traditionally, it has been thought 
that wound re-epithelialization and keratinocyte migration require the support of 
granulation tissue (Gurtner et al., 2008), but in many cases it seems that re-epithe-
lialization is in fact completed before granulation tissue forms, and that granula-
tion tissue is more important in later stages of wound repair such as dermal closure 
and skin remodeling (Braiman-Wiksman et al., 2007; Larjava et al., 1993). Healing 
and remodeling in turn place demands on the nutrition and oxygen supply in the 
wound bed. Local ischemia is common, especially in ruptured tissue with damaged 
blood vessels. These shortages are corrected by angiogenesis, resulting in neovas-
cularization of the inflammatory microenvironment. Angiogenesis in tissue repair 
is activated by the innate inflammatory defense system and proceeds as a tightly 
controlled process, where endothelial cells, smooth muscle cells, and pericytes 
are guided by the microenvironment to sprout, migrate, and form new capillaries 
(Figure 2) (Adams and Alitalo, 2007; Eming et al., 2007).
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Figure 2. Schematic model of endothelial sprouting and neovascularization in response to sig-
nals from stromal fibroblasts and inflammatory cells.
Dynamics of the endothelium during angiogenesis
The purpose of larger blood vessels is to transport oxygen, nutrients, and waste 
products to or from tissues. The actual exchange between vasculature and tissue 
happens in the capillary network. These tiny blood vessels play a crucial role in pro-
viding oxygen and nutrients to surrounding tissue, and they also possess a powerful 
capability to sprout and branch on demand. Proangiogenic stimulation will result 
in altered endothelial cell permeability and loss of microvascular integrity, which 
is required for the formation of new vessels (Wallez and Huber, 2008). Sprout-
ing, the first constructive step in neovascularization, requires dramatic alterations 
in the endothelial cells involved, including the ability to invade and migrate, as 
well as to degrade surrounding ECM (Adams and Alitalo, 2007). Upon angiogenic 
stimulation, a selection is required to define one tip cell to lead the way for a new 
sprout. The surrounding cells must stay in line and suppress their sprouting sig-
naling to prevent serious disorder and formation of a leaking vessel. Recently, it 
was found that the tip cell expresses increased levels of Notch-ligand Delta-like-4, 
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whereas the following stalk cells have activated Notch receptor signaling. The sig-
naling pathway and balance between these two molecules forms the communica-
tion that keeps chaotic vessel formation at bay and provides stability and direction 
to the sprouting response (Hellstrom et al., 2007; Sainson et al., 2005). Vascular 
endothelial growth factor (VEGF) is the master regulator of the sprouting response, 
as it is both essential for the induction of tip cells, as well as for directing the sprout 
through a gradient (Gerhardt et al., 2003; Ruhrberg et al., 2002). Sprouting is fol-
lowed by networking, where endothelial sprouts form connections with each other 
and pre-existing vessels. Lumen formation occurs simultaneously. Finally, newly 
formed vessels mature and are stabilized by the attachment of pericytes onto the 
outer surface. 
Controlled vascular permeability is not only important during leukocyte ex-
travasation, but is also crucial during angiogenesis (Nyqvist et al., 2008). For suc-
cessful endothelial migration and sprouting, cell-cell junctions must loosen up, but 
uncontrolled detachment of cell-cell junctional structures results in disintegrated 
and leaky vessels. Developmental models illustrate the importance of these factors 
in regulating vascular integrity and angiogenesis. VE-cadherin is important in em-
bryonal angiogenesis, and VE-cadherin-deficiency or non-functionality is lethal in 
mice (Carmeliet et al., 1999). ZO-1 is also crucial for normal development: the null 
mutation is embryonally lethal, resulting in defective yolk-sac angiogenesis (Kat-
suno et al., 2008). Angiogenic modulation of vascular integrity also plays a role in 
adulthood, especially in pathological conditions where permeability is chronically 
dysregulated, such as inflammatory diseases and cancer (Nagy et al., 2008). 
Intercellular signaling molecules regulating angiogenesis
The first angiogenic factor was discovered in 1971 by Folkman et al., who iso-
lated a soluble agent from neoplasms responsible for endothelial cell proliferation. 
This factor turned out to be VEGF, a potent driver of angiogenesis, which binds to 
the tyrosine kinase VEGFR2 on endothelial cells (Ferrara et al., 2003; Folkman et 
al., 1971). It is a homodimeric glycoprotein that comes in many splice isoforms, 
some of which are secreted and others of which are bound to cell surface heparin or 
ECM structures. VEGF165 is an abundant isoform and also the most widely studied. 
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In healing wounds, VEGF is mainly produced by stromal fibroblasts and inflamma-
tory leukocytes (Bao et al., 2009; Nissen et al., 1998). 
In addition to proliferation, VEGF also contributes to vascular maintenance by 
promoting survival and preventing apoptosis in endothelial cells. In addition, it in-
creases vascular permeability, which is important in inflammatory reactions, as well 
as in the construction of new vasculature. The interplay between VE-cadherin and 
VEGF has been studied in an in vivo-model of VEGF-dependent angiogenesis: VEGF 
associated with VEGFR2 induced tyrosine phosphorylation on VE-cadherin, and the 
level of phosphorylated VE-cadherin was higher in angiogenic tissues, indicating 
activation of downstream signaling pathways leading to angiogenesis (Lambeng et 
al., 2005). The importance of VEGF signaling in development is demonstrated by 
lethality in a mouse model with a heterozygous knock-out of VEGF (Ferrara et al., 
1996). VEGF exhibits a temporal pattern of expression in healing wounds (Bao et 
al., 2009; Brown et al., 1992; Kumar et al., 2009), and maximal levels of VEGF occur 
simultaneously with granulation tissue formation, approximately 3 to 7 days post-
wounding (Brown et al., 1992). VEGF and VEGFR2 levels remain elevated long into 
the scar phase (Kumar et al., 2009), indicating the importance of VEGF signaling in 
later remodeling functions. 
Hepatocyte growth factor or scatter factor (HGF or SF) is another growth factor 
with an important role in the tissue repair process. Its main source is the stromal 
fibroblast, and it promotes various functions, such as cell motility, proliferation, 
morphogenesis, and matrix construction in several cell types, such as hepatocytes, 
endothelial cells, epithelial cells, melanocytes, and keratinocytes (Conway et al., 
2006; Nakamura et al., 1986; Weidner et al., 1991). It is secreted in an inactive 
form, and activated by proteolytic cleavage in damaged tissues, mainly by the ser-
ine protease HGF activator (HGFA) (Miyazawa et al., 1996). Known HGFA activa-
tors are the HGF-converting enzyme, as well as components of the coagulation 
cascade such as thrombin, urokinase-type plasminogen activator, tissue-type plas-
minogen activator, and blood coagulation factor XIIa (Conway et al., 2006; Mars et 
al., 1993; Miyazawa et al., 1996; Shimomura et al., 1993; Shimomura et al., 1995). 
HGF binds to its receptor MET (mesenchymal-epithelial transition factor), which 
is present mostly on epithelial cells, but also on endothelial cells (Birchmeier et 
al., 2003; Nakamura et al., 1995; Park et al., 1986; Sonnenberg et al., 1993). HGF 
is now also recognized as a promoter of angiogenesis and lymphangiogenesis and 
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functions by encouraging proliferation, migration, and sprouting of vascular and 
lymphatic endothelial cells (Bussolino et al., 1992; Kajiya et al., 2005). MET plays 
an important role in wound healing, since the presence of MET in keratinocytes is 
obligatory for successful wound re-epithelialization. MET signaling leads to activa-
tion of motogenic signaling pathways, actin polymerization, and the formation of 
focal adhesions and stress fibers, all required for cell migration (Chmielowiec et al., 
2007). 
CXC-chemokines possessing the ELR motif (Glu-Leu-Arg motif), such as 
CXCL1-8, have angiogenic capabilities and stimulate endothelial cell chemotaxis 
(Strieter et al., 1995). All these chemokines bind to CXCR2, which is suspected to be 
the main pro-angiogenesis signal mediator (Keeley et al., 2008). Also ELR-negative 
CC-chemokines can also be angiogenic, for example CCL2 promotes angiogenesis 
in several in vivo models (Salcedo et al., 2000). 
Recent research has linked together COX-2 expression, chronic inflammation, 
and increased angiogenesis (Chang et al., 2004; Wang et al., 2005). The angiogenic 
effects of COX-2 can be grouped into three categories: induction of endothelial 
cell proliferation, enhancement of survival, and stimulation of cell adhesion and 
migration (Monnier et al., 2005). The COX-2 products, prostaglandins, have been 
shown to stimulate expression of VEGF and HGF (Liu et al., 1999; Matsunaga et al., 
1994), and upregulation of COX-2 is known to be associated with HGF-promoted 
angiogenesis (Boccaccio et al., 2005). 
In addition to playing a major part in directing the general proinflammatory 
response, the transcription factor NF-κB has an important role in angiogenesis. 
It controls the transcription of many secreted signaling molecules, such as VEGF 
and several proangiogenic chemokines (Freter et al., 1996; Kiriakidis et al., 2003; 
Martin et al., 1997; Mauviel et al., 1992; Tabruyn and Griffioen, 2008), as well as 
the induction of COX-2 (Newton et al., 1997). In addition, it promotes the survival 
of endothelial cells (Scatena et al., 1998; Zen et al., 1999). On the other hand, 
recent results also indicate a possible inhibitory effect of NF-κB in tumor-related 
angiogenesis, as repression of NF-κB resulted in increased tumor vascularization 
(Kisseleva et al., 2006). Hence, it would seem that NF-κB can have two very differ-
ent effects on angiogenesis.
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Role of stromal fibroblasts in angiogenesis
The stromal microenvironment plays a crucial role in supporting neovascular-
ization in healing wounds. Several publications have demonstrated the importance 
of stromal fibroblasts as promoters of sprouting and lumen formation, both in 
in vitro and in vivo models (Hughes, 2008; Klagsbrun et al., 1976; Montesano et 
al., 1993; Nakatsu et al., 2003). Nevertheless, as fibroblasts are a heterogeneous 
group of cells, their capability for inducing endothelial sprouting and tubulogenesis 
seems to vary between strains (Klagsbrun et al., 1976; Montesano et al., 1993). It 
has become apparent that fibroblasts promote angiogenesis by secreting soluble 
factors such as prostaglandins (Wang et al., 1996; Zhang et al., 1998), cytokines 
(Brouty-Boyé et al., 2000; Lukacs et al., 1994), HGF (Weidner et al., 1991), and 
VEGF (Nissen et al., 1998). Fukumura et al. observed VEGF in granulation tissue 
around wounds, and they noted that the strong stromal VEGF signal originated 
mainly from fibroblasts (Fukumura et al., 1998).
Fibroblast proximity is important for many endothelial cell functions. An in 
vitro model with reconstructed connective tissue showed that the presence of fi-
broblasts as well as ECM was necessary for tubulogenesis (Berthod et al., 2006), 
but in vivo the situation may be more complex. Nevertheless, fibroblasts are an 
important source of fibronectin and thereby could also promote angiogenesis by 
proxy (Hughes, 2008). The ECM protein fibronectin has been shown to promote 
angiogenic properties in endothelial cells including adhesion, growth, and survival, 
as well as the biological activity of HGF and VEGF (Rahman et al., 2005; Sottile, 
2004; Wijelath et al., 2002). Hence, angiogenesis seems to be promoted by both 
ECM and its component fibronectin, as well as by matrix-producing fibroblasts.
Nemosis is a model for the stromal activation process of fibroblasts
In 2004, our laboratory discovered an experimental model for fibroblast activa-
tion. Depriving normal, primary, human foreskin fibroblasts of growth support by 
coating a U-well culture dish with a thin film of agarose resulted in their clustering 
into compact spheroidal structures. Clustering is not dependent on the coating ma-
terial of the culture wells, as the nemosis response remained similar with poly(2-
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hydroxyethylmethacrylate; polyHEMA) as coating material, and also occurred 
when we used the hanging-drop culture method (Bizik et al., 2004; Salmenperä 
et al., 2008). In our laboratory, 10-20 000 cells per spheroid are used, but early 
unpublished observations have indicated that this cell number is not critical for the 
nemosis response. Compact spheroids are formed within 24 hours (Figure 3), and 
around that time dramatic changes in mRNA and protein expression profiles take 
place. Simultaneously, the spheroids begin to decompose, displaying necrotic mor-
phology. No upregulation of apoptosis markers such as Fas, Daxx, and activated 
caspase-3 is observed, nor is presence of fragmented DNA seen (Bizik et al., 2004). 
Initially this novel, programmed, necrosis-like cell death was thought to be a key 
element in nemosis, as a number of cells in the spheroid are dying. However, other 
cells seem to remain viable for at least five days, and as later research established 
similarities to stromal and cancer-associated fibroblasts, the actual role of such 
fibroblast death in vivo has not been determined.
 3h 6h 12h
 24h 48h 72h 96h
Figure 3. Time-points depicting the clustering process of human primary dermal fibroblasts, 
resulting in a compact spheroidal structure. 
Because of the apparent links to cell death as well as host defense and tissue 
repair, this fibroblast activation model was named “nemosis”, after Nemesis, the 
Greek goddess of retribution and inevitable consequences (Kankuri et al., 2005; see 
Table 2 for an overview and proposed timeline of nemosis).
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6 h 24 h 48 h 72 h 96 h
Fibronectin Fibronectin HGF induction VEGF induction High levels
production decrease   of IL-1, -6,
    -11, GM-CSF,
    LIF 
  COX-2  MMP-10
  induction induction
  MT1-MMP,
  TIMP-1
  induction
  Membrane
  leakage   
  Necrotic
  morphology
  observed  
  Prostaglandin
  induction
Table 2. Overview and proposed timeline for nemosis. Induction of growth factors, MMPs and 
cytokines analyzed as secreted protein; fibronectin and COX-2 as expressed protein. GM-CSF: 
granulocyte macrophage-colony stimulating factor; LIF: leukemia inhibitory factor 
(Bizik et al., 2004; Kankuri et al., 2005; Kankuri et al., 2008; Räsänen et al., 2008; Salmenperä 
et al., 2008; Sirén et al., 2006).
Allowing fibroblasts to cluster into spheroids leads to the induction of COX-2 
and the production of prostaglandins E2, I2, and F2α. COX-2 is induced throughout 
the spheroid and peaks around 60-72 hours. The selective COX-2 inhibitors indo-
methacin and NS-398 were able to inhibit not only COX-2 activity and prosta-
glandin synthesis, but also the expression of COX-2. Spheroid formation was not 
affected. The expression of the non-inducible, ubiquitous COX-1 persists long into 
the process (Bizik et al., 2004). We have been unable to find any markers for oxida-
tive stress or hypoxia in the spheroid. Also, we have noted that the induction of the 
hypoxia-inducible COX-2 is uniform and not restricted to the center of the spher-
oid, as could be the case in hypoxia. 
Interestingly, the nemosis response is not constant between fibroblast strains. 
Measured as COX-2 induction and the production of VEGF and HGF, along with 
cancer-associated fibroblast markers such as fibroblast-specific protein 1, α-SMA, 
and fibroblast activation protein, it varies slightly among primary human fibroblast 
strains, as well as between normal and cancer-associated fibroblasts, underscoring 
the heterogeneity of the fibroblast (Räsänen et al., 2009).
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Early steps in nemosis of fibroblasts: interactions with the extracellular matrix
The ECM protein fibronectin mediates cluster formation during the compaction 
stage, as demonstrated by the fact that fibronectin knock-out or RNAi-silenced 
cells form loose clusters instead of compact spheroids (Salmenperä et al., 2008). 
Fibroblasts are known to bind fibronectin mainly via α5β1 and αvβ1-integrins, and 
the importance of these integrins in the initial compaction of single, scattered cells 
into a firm spheroid is illustrated by the delayed spheroid formation that occurred 
when α5 or β1-integrins were functionally blocked, resulting in a loose spheroid for 
the first 12 hours (ibid). A similar effect was seen if the fibronectin in the cells pos-
sessed a mutated integrin binding site (RGE (Arg-Gly-Glu)-amino acid sequence 
instead of RGD (Arg-Gly-Asp)) (ibid). Blockage of αv and β1, as well as specific 
blockage of the fibronectin RGD site, resulted in the loss of COX-2 induction, indi-
cating a role for fibronectin in nemotic activation of fibroblasts (ibid). In conclusion, 
nemotic activation of the clustering fibroblasts seems to result from fibronectin-
integrin interactions that take place during the initial compaction stage .
Proteolysis is an important event in tissue remodeling during tissue repair (Gill 
and Parks, 2008). Nemosis also leads to an upregulated expression of extracellular 
matrix metalloproteinases MMP-1, -10, and membrane type-1-MMP (MT1-MMP), 
and the latter two are also secreted in higher amounts. Furthermore nemotic fibro-
blasts display proteolytic activity caused by MMPs (Siren et al., 2006). Many MMPs 
are known to modify inflammatory responses by cleaving and processing cytokines 
and growth factors (Van Lint and Libert, 2007). Moreover, several MMPs, such as 
MMP-10, are also implicated in wound healing (Gill and Parks, 2008; Rechardt et 
al., 2000), whereas the expression of the soluble form of MT1-MMP, known to be 
produced by fibroblasts, can be upregulated in inflammatory conditions (Li et al., 
1998; Maisi et al., 2002). Plasminogen activation and an increased generation of 
plasmin also takes place during nemosis, and these processes are mainly regulated 
by exposure to α-enolase on the cell surface (Bizik et al., 2004). As MMP and plas-
min inhibitors did not affect spheroid decomposition significantly, it was suggested 
that proteolysis is targeted to the surrounding cells and not to the nemotic fibro-
blasts themselves (Siren et al., 2006). 
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Influence of nemotic fibroblasts on epithelial cells
During wound repair, one of the main goals of the stroma is to support healing 
processes such as dermal closure and remodeling (Braiman-Wiksman et al., 2007). 
Keratinocytes are crucial in early events of wound repair, and their migration and 
proliferation is needed to close the wound with a new protective layer. The HaCaT 
cell line is a spontaneously immortalized skin keratinocyte cell line (Boukamp 
et al., 1988), which has been shown to modify nemotic activation of fibroblasts, 
determined as abolished COX-2 expression. In a model with an increasingly ma-
lignant HaCaT cell panel (immortalized, benign, malignant, and metastatic lines) 
representing squamous cell carcinoma progression (Mueller and Fusenig, 2002), 
the more malignant types were shown to behave in an opposite manner by in-
creasing the expression of COX-2 and production of growth factors (Räsänen et al., 
2008). The more malignant HaCaT cell types induce the production of keratinocyte 
growth factor, HGF, and VEGF in nemotic fibroblasts (ibid). Nemotic fibroblasts in 
turn increase the proliferation and motility of HaCaT cells (Räsänen and Vaheri, 
2010). These signaling processes indicate a paracrine cross-talk between epithelial 
cells and nemotic fibroblasts.
Bone marrow mesenchymal stem cells have also been shown to undergo ne-
mosis, during which they induce their COX-2 expression and produce high levels of 
HGF. Nemotic bone marrow mesenchymal stem cells induce keratinocyte scratch 
wound closure in vitro in an HGF/MET/phosphoinositide-3-kinase-dependent man-
ner (Peura et al., 2009). Since bone marrow mesenchymal stem cells are present 
in skin wounds (Badiavas et al., 2003), inducing keratinocyte proliferation through 
nemosis suggests interesting possibilities for wound healing and tissue regenera-
tion.
Influence of nemotic fibroblasts on malignant cells
Many inflammatory processes are also occurring during tumorigenesis, and the 
link between inflammation and cancer is being intensely investigated (Mantovani 
et al., 2008). Indeed, inflammation has been proposed to be the seventh hallmark 
of cancer (Colotta et al., 2009), in addition to the six generally acknowledged steps 
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in tumorigenesis as laid out by Hanahan and Weinberg (Hanahan and Weinberg, 
2000). Tumors seem to be capable of inducing and redirecting tissue healing re-
sponses for the benefit of cancer progression, among other things by recruiting in-
flammatory cells and fibroblasts that together make up the stroma surrounding the 
tumor. These stromal cell types secrete large amounts of cytokines, chemokines, 
metalloproteases and growth factors that promote further growth and develoment 
of the tumor (Tlsty and Coussens, 2006). Some types of tumors consist mostly 
of stromal cells including fibroblasts, which have been shown to promote tum-
origenesis. These fibroblasts are also called cancer-associated fibroblasts or CAFs 
(Schurch et al., 1981). 
Activated, nemotic fibroblasts produce and secrete abundant amounts of HGF, 
which promotes the invasive behavior of melanoma and carcinoma cells that ex-
press the functional HGF receptor MET (Kankuri et al., 2005). On the other hand, 
MET expression by nemotic fibroblasts was shown to decrease, which suggests that 
the HGF production is probably for paracrine signaling purposes. MET-negative 
leukemia cells respond differently: when stimulated by nemotic fibroblasts they 
undergo growth arrest and differentiation to a dendritic phenotype (Kankuri et al., 
2008). The studies above show that nemotic fibroblasts are able to direct changes 
in phenotype in tumor cells, as well as changes in their behavior. Interestingly, con-
ditioned medium from Bowes melanoma cells induced spontaneous clustering of 
fibroblasts in vitro, forming clumps much like artificially formed fibroblast spher-
oids (Kankuri et al., 2005). Such an effect suggests parallels to the cross-talk taking 
place between tumor cells and CAFs. 
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Aims of the study
This study was undertaken to characterize fibroblast nemosis and the different 
ways it could promote and regulate proinflammatory and proangiogenic proper-
ties. In addition, this study attempted to shed light on how nemosis, or its pos-
sible in vivo counterpart, could contribute to the emergence and progression of 
inflammation, with possible implications for inflammation-related tumorigenesis, 
another aspect of nemosis investigated by our group. The study was divided into 
three sub-projects, which together constitute this doctoral thesis:
1. Do nemotic fibroblasts produce chemoattractants and call  
leukocytes?
An initial microarray analysis conducted to profile the nemotic response of fi-
broblasts on the gene expression level showed that nemotic activation led to up-
regulation of many chemokines. We aimed to validate the chemokine profile and 
further investigate its effect on leukocytes. We hypothesized that nemotic fibro-
blasts secreted chemokines and that they would promote leukocyte migration. 
Nuclear factor-κB (NF-κB) is an important component regulating cytokine gene 
expression and other mechanisms leading to a proinflammatory response. There-
fore, we hypothesized that NF-κB was activated in nemotic fibroblasts and regu-
lates chemokine production.
2. Do nemotic fibroblasts activate endothelial cells?
Since nemotic fibroblasts were shown to display inflammation-promoting and 
leukocyte-attracting properties, we hypothesized that they were also capable of 
activating endothelial cells and leukocytes, resulting in enhanced leukocyte ad-
hesion on endothelium. We also hypothesized that activated, nemotic fibroblasts 
could increase the permeability of the endothelial layer, aiding extravasation of 
leukocytes into tissues. We aimed to examine the influence of nemotic fibroblast 
medium on leukocyte adhesion onto endothelial monolayers, as well as screen for 
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surface markers on the endothelial cells. Furthermore, we aimed to investigate 
permeability-related changes in the adherens and tight junction proteins of en-
dothelial cells in a monolayer.
3. Do nemotic fibroblasts promote angiogenesis?
Our group found that nemotic fibroblast spheroids produced and secreted large 
amounts of HGF, a growth factor which promotes cell proliferation and angiogen-
esis. Furthermore, our group has shown that HGF produced by nemotic fibroblast 
spheroids promotes scattering and invasiveness of c-Met-expressing human cancer 
cells (Kankuri et al., 2005). Production of VEGF was also elevated in nemotic spher-
oids when compared to fibroblast monolayer cultures (Räsänen et al., 2008). These 
clues led us to investigate the angiogenic potential of nemotic fibroblasts.
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Materials and methods
The materials and methods used in this study are summarized below. Detailed 
descriptions, including parallel experiment repetition numbers and statistical anal-
yses, can be found in the original publication(s) indicated by the Roman numeral 
in question.
Cell isolation, culture, and initiation of nemosis in fibroblasts (I, II, III)
Human cell types used in this study are given in Table 3 (see following page). All 
cells were routinely cultured in a humidified, 5% CO2 atmosphere. Adherent cells 
were detached by trypsinization.
Neutrophils were freshly isolated from whole blood on the day of the experi-
ment and diluted with trisodium citrate and BSA, layered over isotonic Ficoll-Paque 
dextran (Amersham Biosciences), and centrifuged with density gradient separation 
(Roos and de Boer, 1986). Erythrocytes in the granulocyte fraction were removed 
by lysis with isotonic NH4Cl, and the remaining granulocyte fraction was washed. 
The purity of neutrophils was >97%. 
The nemotic activation process of fibroblasts was initiated by allowing 104 cells 
to cluster upon a nonadhesive surface (96-well U-bottom plate coated with 0.8% 
low melting-point agarose), thus forming a spheroid structure. Monolayer cultures 
of fibroblasts were used as a control, and these were directly seeded onto flat-bot-
tom plates at an identical concentration. In chemotaxis experiments and the assay 
for CCL5 production (I) media were concentrated: spheroids were harvested at 24 
h, concentrated to 48 spheroids/ml and grown in 12-well flat-bottom plates until 
further use. Monolayer cultures were directly seeded onto 12- or 96-well plates at 
a corresponding concentration. 
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Cell type name Description Publication(s) Source
HFSF Primary foreskin I In-house
 fibroblast  isolation
CRL-2088 Primary foreskin II, III American Type
 fibroblast  Culture Collection
PMN Primary poly- I Freshly isolated, 
 morphonuclear   in-house
 neutrophil
THP-1 Leukemic mono- I, II American Type 
 cyte cell line   Culture Collection
HAL Primary adult lung I In-house
 fibroblast   isolation
HES Primary embryonal I In-house
 skin fibroblast   isolation
MCR-5 Primary embryonal I American Type 
 lung fibroblast   Culture Collection
HUVEC Primary umbilical II, III In-house, by
 vein endothelial  Dr. H. Koistinen,
 cell isolation  University of
   Helsinki
HMEC-dNeo Primary neonatal III by Dr I. Virtanen,
 dermal  University of
 microvascular  Helsinki,
 endothelial cell  originally pur-
   chased from
   Clonetics/Lonza 
Table 3. Cell lines (all human) used in this study.
Microarray experiments and analysis (I)
Total RNA from corresponding fibroblast spheroid and monolayer samples was 
extracted by Trizol Reagent (Invitrogen) and purified using the RNeasy kit (QIA-
GEN). The quality of the mRNA was assessed using a Bioanalyser 2100 (Agilent 
Technologies). Biotinylated cRNAs were prepared according to manufacturer’s 
instructions (Affymetrix), fragmented, and hybridized to Affymetric HG-U133A 
GeneChips using standard conditions in the Affymetrix fluidics station.
Scanned arrays were analyzed by Affymetrix Microarray Suite 5.0 software by 
omitting obvious artifacts and outliers, scaling raw expression intensity, and adjust-
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ing mean signal of probe sets to a user-specified 500. The gene expression profiles 
were compared using GeneSpring™ software and normalized both “per chip” and 
“per gene”, as well as filtered for “molecular function: chemokine”. The resulting list 
was reduced to those classified as chemokines by the IUIS/WHO Subcommittee on 
Chemokine Nomenclature (Thorpe et al., 2003). 
Quantification of growth factors and chemokines in conditioned  
fibroblast medium (I, III)
Conditioned media were collected from nemotic fibroblasts and monolayers at 
different time points. Quantification of CCL2, CCL3, CCL5 (R&D Systems), CXCL8 
(Sanquin Reagents), and VEGF (R&D Systems) in the conditioned medium was car-
ried out by ELISAs according to the manufacturers’ instructions. The media for the 
CCL5 assay were concentrated as described on page 33.
Chemotaxis assay (I)
The chemotactic activity of conditioned fibroblast media was assayed for pri-
mary neutrophils and the monocytic THP-1 cells using a Boyden chamber setup. 
Leukocytes were labeled with fluorescent Calcein-AM (Molecular Probes/Invitro-
gen) and placed in the upper chamber of a Transwell plate system (Costar/Corn-
ing). Conditioned nemotic fibroblast or monolayer medium was added to the lower 
well, and leukocytes were allowed to migrate through a porous membrane (pore 
size 3 µm) in cell culture conditions. Transmigrated cells in the bottom well as well 
as cells attached to the membrane were lysed with an HTAB-based buffer and the 
fluorescence measured with a fluorometer (Wallac Victor2 1420, PerkinElmer).
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Determination of IκB levels and NF-κB activity (I)
IκB was detected by immunoblotting: whole-cell samples were processed for 
SDS-PAGE and the separated protein bands transferred to a nitrocellulose mem-
brane, which was then probed with anti-IκB antibody and a secondary antibody 
with an HRP conjugate. The ECL signal was detected on X-ray film by the Super-
Signal West Pico substrate kit (Pierce Biotechnology). To detect changes in protein 
levels, densitometric analysis of the bands was carried out using a ChemiDoc XRS 
instrument and Quantity One software (Bio-Rad). Band intensities were normal-
ized to actin at corresponding time points to yield relative values.
NF-κB levels were analyzed from nuclear extracts. The extraction was per-
formed using the Nuclear Extraction Kit by Cayman Chemical, and nuclear protein 
concentrations were assessed by the DC Protein Assay kit (Bio-Rad). NF-κB activ-
ity was analyzed by an enzyme-linked, immunosorbent NF-κB (p65) Transcription 
Factor Assay Kit (Cayman Chemical). Briefly, nuclear extract samples were normal-
ized for protein load and the total volume incubated with NF-κB consensus se-
quence DNA pre-bound to a sample well plate, after which a p65-specific antibody 
and an HRP conjugate were added. Finally, the relative NF-κB activity was detected 
by a colorimetric readout. 
Analysis of tight and adherens junctions on endothelial 
monolayers (II)
HUVECs were grown on gelatin-coated coverslips to confluence for 96 h, fol-
lowed by incubation with conditioned spheroid or monolayer medium. Coverslips 
were collected at various time points, fixed with paraformaldehyde and permeabi-
lized with Triton X-100 (VE-cadherin, ZO-1), or fixed with acetone (claudin-5), and 
stored in PBS at +4°C until further use.
Samples were stained for immunofluorescence with primary antibodies 
(ZO-1, VE-cadherin, claudin-5) and conjugated secondary antibodies (Alexa-488). 
Nuclei were stained with Hoechst 33342 dye. Finally, the coverslips were mounted 
on glass slides with mounting medium (SlowFade Gold, Molecular Probes/Invitro-
gen). Images were captured with a Zeiss Axioplan2 microscope (Carl Zeiss Micro-
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Imaging) connected to a Hamamatsu CCD camera (Hamamatsu Photonics).
Static leukocyte adhesion assay (II)
HUVECs were plated on 24-well plates and grown to confluence for 96 h fol-
lowed by stimulation with either monolayer or spheroid medium for 4 hours. GFP-
expressing THP-1 cells were added, and the samples were incubated for 2 hours in 
cell culture conditions with or without function-blocking anti-β2-integrin antibod-
ies (clone E74; the kind gift of Dr. C. Gahmberg, University of Helsinki). Nonadher-
ent cells were washed away, the remaining cells were lysed, and GFP fluorescence 
was measured directly from the wells with a fluorometer. 
Scratch-wound repair assay and live-cell imaging (III)
For the scratch-wound repair assay, endothelial cells were seeded on multiwell 
plates and grown to confluence, after which they were scratch-wounded with a 
pipette tip. The growth medium was replaced with conditioned nemotic fibroblast 
or monolayer medium, with or without function-blocking anti-HGF or anti-VEGF 
antibodies (R&D Systems). Cells were fixed with paraformaldehyde, permeabilized 
with Triton X-100, and stained with Hoechst dye 33342 for nuclear DNA visualiza-
tion. Samples were imaged with an Olympus CKX41 inverted microscope, a UPlan 
Fluorite phase-contrast objective, and an Olympus DP12 CCD camera system. 
Analysis of the images was carried out with custom-made software (Molecular 
Imaging Unit Core Facility at Biomedicum Helsinki, Faculty of Medicine, Univer-
sity of Helsinki, Finland) on a Matlab platform (MathWorks Inc.), yielding a relative 
value representing the cell-free area for each image.
The scratch-wound closure process was also followed in real-time with a Cell-
IQ cell culturing platform (Chip-Man Technologies), equipped with a phase-con-
trast microscope (Nikon CFI Achromat) and camera. The system was computer-
controlled by Imagen software (Chip-Man Technologies). The experimental set-up 
was identical to the scratch-wound assay, and images were captured at 30-minute 
intervals for 24 hours. Analysis was carried out with ImageJ software (Rasband, 
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1997), using the Manual Tracking plug-in. Images were stacked and the movements 
of eight cells on the wound edge per image were tracked.
Endothelial sprout formation assay (III)
Endothelial cells were plated on polymerized Growth Factor Reduced Matrigel® 
basement membrane matrix (BD Biosciences) and covered with conditioned nem-
otic fibroblast or monolayer medium with or without function-blocking anti-HGF 
and anti-VEGF antibodies. Plates were incubated for 24 hours, after which phase-
contrast images were randomly captured with an Olympus CKX41 inverted micro-
scope connected to a DP12 CCD camera (Olympus). Image analysis was carried 
out with ImageJ software. Sprout length was assessed as the distance between two 
branching points and scaled back to micrometers. 
Proliferation assay (III)
HUVECs were plated onto 6-well plates (50 000 cells/well) and cultured for 24 
h. The culture medium was then replaced with conditioned nemotic fibroblast or 
monolayer medium and incubated for a further 48 hours. Phase-contrast images 
were captured at various time points and analyzed by counting the number of cells 
per image. Counting was carried out with ImageJ software, using the Particle Analy-
sis/Cell Counter plug-in. 
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Results and discussion
The main results of the study are presented and discussed here. For a more 
detailed description and discussion the reader is referred to the original research 
publications indicated with corresponding Roman numerals.
Nemotic fibroblasts exhibit a proinflammatory response (I, II, IV)
Research has unveiled a new functional role for fibroblasts. Instead of only play-
ing a structural role in the construction and maintenance of ECM, fibroblasts are 
now also seen as modulators of the inflammatory defense response in tissue (Ba-
glole et al., 2006; Flavell et al., 2008). Activated fibroblasts in the inflammatory 
stroma are known to produce an array of chemokines that attract leukocytes, and 
to activate and uphold the inflammation response through an array of secretory 
molecules such as cytokines, matrix metalloproteinases, and growth factors.
Production of chemotactic cytokines and attraction of leukocytes 
Nemosis is a model for stromal activation of fibroblasts. Upon clustering, ex-
tensive changes take place, and the fibroblasts convert to an increasingly secre-
tory, proinflammatory phenotype, producing among other factors prostaglandins, 
proteolytic enzymes, and growth factors (Bizik et al., 2004; Kankuri et al., 2005; 
Räsänen et al., 2009; Sirén et al., 2006; reviewed in (IV)). The proinflammatory 
response is further enhanced by the production of chemotactic cytokines, as de-
scribed in this study (I). Nemotic fibroblasts upregulate the mRNA levels of several 
chemokines (Table 1). They also secrete these chemokines in significantly higher 
amounts than fibroblasts in monolayer cultures already at 36 h after cell seed-
ing. Microarray analyses provided a set of chemokines with over five-fold increased 
expression compared to monolayer cultures, with top fold-increase values of >100 
(CCL3 and -5). The chemokines CXCL1-3 were not studied further because of their 
double nature as growth factors and chemoattractants, and CCL4 because of 
its low signal intensity level. The remaining chemokines, CCL-3, -5, and CXCL8, 
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were also secreted at significantly higher levels by the nemotic fibroblasts than by 
monolayer cultures after 72 hours, with XCXL8 levels reaching as high as 40 ng/ml 
in the standard set-up of 104 fibroblasts seeded in 150 µl medium. Only CCL2 did 
not follow the pattern; microarray experiments showed a higher concentration of 
mRNA in nemotic fibroblasts, but secreted protein levels remained lower than in 
monolayers. In endothelial cells it seems that CCL2 could be stored intracellularly 
but not secreted (Øynebråten et al., 2004; Øynebråten et al., 2005), and a similar 
phenomenon could perhaps also take place in nemotic fibroblasts, although this 
was not further investigated.
The production of cytokines seems to be an intrinsic property of fibroblasts both 
in vitro and in vivo, in that a basal level of cytokine production is constantly main-
tained. Fibroblasts in inflamed areas are known to display an altered chemokine 
profile (Brouty-Boyé et al., 2000; Hogaboam et al., 1998; Lukacs et al., 1994). Pro-
duction of chemotactic cytokines indicates a paracrine effect, and the chemokine 
profile produced by nemotic fibroblasts points to leukocytes as target cells. Indeed, 
in this study we showed that conditioned medium of nemotic fibroblasts was able 
to attract both neutrophils and monocytic THP-1 cells, with an increase of 1.4 and 
6.4-fold, respectively (I). Chemotaxis was partially dependent on CXCL8 (maximal 
inhibition 24% with antibodies) with regard to neutrophils, and CCL3 and CCL5 
with regard to THP-1 cells (maximal inhibition of the CCL3 and CCL5 receptor CCR1 
was 38%). CCL5 functions as an activator and chemoattractant of T cells (Schall 
et al., 1990). Furthermore, nemotic fibroblasts have been shown to produce the 
cytokines IL-1, -6, -8, -11, leukemia inhibitor factor, and granulocyte-macrophage 
colony-stimulating factor, as well as to induce dendritic differentiation of leukemic 
cells such as THP-1 (Kankuri et al., 2008), which widens the profile for the effects of 
fibroblast spheroid-mediated inflammatory activation of leukocytes. 
Expression of many cytokines is regulated by the transcription factor NF-κB, 
which was also found to be activated in nemosis, as shown in this study (I). The two 
components of the classical NF-κB pathway, p65 and p50, were present in nemotic 
fibroblasts with stable expression levels throughout the nemosis progression from 
0 to 96 hours. The endogenous inhibitor IκB was degraded in a fluctuating pattern 
with dips at 36 and 48 hours, suggesting periodic boosts in NF-κB activity. Func-
tionally, NF-κB was more active in nemotic fibroblasts than in monolayer cultures 
at the aforementioned time points. Fibronectin is produced especially during the 
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first 24 hours of nemosis (Salmenperä et al., 2008) and is known to activate NF-
κB, at least in epithelial cells (Kolachala et al., 2007). If a similar activation exists in 
nemotic fibroblasts, a possible feed-back loop may take place during the compac-
tion stage.
It has been proposed that chronic inflammation happens when immunoactive 
fibroblasts fail to switch off, and that fibroblasts would thus play an important 
role in the attenuation of inflammation (Buckley et al., 2001). The mechanism for 
attenuation in fibroblasts is unknown, but according to some studies, fibroblast 
RelB is capable of stabilizing IκB, which in turn switches off NF-κB and thus also 
the plethora of proinflammatory molecules produced by the fibroblasts (Lo et al., 
1999; Xia et al., 1997). Constitutively active NF-κB is often reported in inflammato-
ry pathologies (Tak and Firestein, 2001); hence, active NF-κB in stromal fibroblasts 
could point to it having a possible role in persisting inflammation.
Leukocytes play an important role in another mechanism for the attenuation 
of inflammation. The production of prosolving lipid metabolites downregulates 
cytokine expression, regulates macrophage phagocytosis, and inhibits neutrophil 
infiltration (Serhan et al., 2008). These lipid mediators are mainly produced by 
mucosal and vascular cells, as well as leukocytes and platelets. COX-2 is required 
for the production of many of these mediators, by way of acting as a switch in en-
zymatic function that results in production of anti-inflammatory molecules such 
as lipoxins, protectins, and resolvins (ibid). PGE2, a COX-2 end product tradition-
ally viewed as proinflammatory, has been shown to induce lipoxin production in 
leukocytes (Levy et al., 2001), suggesting a feed-back mechanism that promotes 
homeostasis. Fibroblasts in nemosis seem to share properties with inflammation-
promoting fibroblasts, but as two of the characteristics of nemosis are COX-2 up-
regulation and PGE2 production, the possible implication of this for the resolution 
process of inflammation should be considered.
All experiments on nemotic fibroblasts in this study have been conducted in 
comparison with fibroblast monolayer cultures, a traditional way of observing 
mesenchymal cells. The suitability of monolayer cultures in comparison to cultures 
with spheroidal structures can be discussed, especially in the light of how cells 
react to 2D versus 3D environments. Cukierman et al. have performed extensive 
studies on fibroblasts in 3D cultures, showing clear differences in fibroblast pheno-
type when grown in different lattices such as collagen and ECM (Cukierman et al., 
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2001; Cukierman et al., 2002). Fibroblasts in stressed collagen and ECM are known 
to proliferate, whereas a relaxed collagen matrix causes quiescence. In contrast, at 
least some of the nemotic fibroblasts seem to suffer a necrosis-like fate. Adhesion 
of 3D-grown fibroblasts was shown to be dependent on the integrin α5β1, and cel-
lular responses such as migration and proliferation on α5 (Cukierman et al., 2001). 
Both α5 and β1 regulate clustering in the nemosis model (Salmenperä et al., 2008). 
While 3D cultures and nemosis may share properties, proliferation arrest, along 
with the induction of growth factors, prostaglandins, cytokines, and MMPs seen in 
nemosis, suggest that nemosis is not identical to fibroblasts grown in 3D lattices. 
Still, a careful study of spheroid structures grown in different lattices may yield 
information indicating whether one of them provides a better control environment 
than conventional monolayer culture.
Activation of endothelium and modulation of its permeability 
Leukocytes, especially monocyte-macrophages, are a crucial part of the first 
line of defense against harmful agents. They also play an important part in direct-
ing inflammatory and tissue repair responses. For these circulating blood cells to 
home to inflamed tissue they must be alerted by signals from the site of inflam-
mation that reach into the vascular compartment (Chavakis et al., 2009; Granger 
and Kubes, 1994; Muller 2009). The task of alerting leukocytes is carried out by 
the vascular endothelium. The endothelium lines vessel walls and provides a body-
wide sensory system for damage alerts from within tissue. Only activated endothe-
lium is known to be able to bind leukocytes, and such activation can be induced by 
stromal components such as fibroblasts (Maiellaro and Taylor, 2007; Zimmerman 
et al., 1999).
This study shows that activated, nemotic fibroblasts promote adhesion of 
monocyte-like THP-1 cells onto a HUVEC monolayer by 82%. The adhesion is 
partly β2-integrin-dependent, as a blocking antibody inhibited adhesion by 15%. 
A blocking antibody against β1-integrin had no inhibitory effect (II). Firm adhe-
sion of leukocytes is part of the extravasation process, and mediated through β2-
integrins on the leukocyte and ICAM-1 on the endothelium (Gahmberg et al., 1997, 
Gahmberg et al., 2009; Lawson and Wolf, 2009). However, the results suggest that 
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β2-integrin-dependent adhesion is not the major adhesion mechanism in nemosis-
mediated leukocyte adhesion to endothelium.
Circulatory leukocytes must cross the endothelial barrier of the vascular wall 
in order to access the underlying injury site. Access is granted by activated en-
dothelial cells that downregulate the expression of cell-cell junctions, thus locally 
increasing the permeability of the vessel structure. This study describes an effect of 
nemotic fibroblasts on endothelial cell junctions in vitro (II). Conditioned medium 
from nemotic fibroblasts causes removal of the tight junction component clau-
din-5 and adherens junction component VE-cadherin, both membrane-bound pro-
teins, from endothelial monolayer cell-cell junctions after 6 hours of stimulation 
with nemotic fibroblast medium. Claudin-5 and VE-cadherin interact with ZO-1 
on the cytosolic side, which was also downregulated after 24 hours. While clau-
din-5 and VE-cadherin levels seemed to diminish, ZO-1 expression seemed to shift 
to the cytoplasm, indicating internalization and higher persisting levels of protein 
within the cells. Interestingly, claudin-5 was inconsistently expressed in some cells 
but not others, suggesting heterogeneity in the HUVEC cells. β-cadherin, another 
cytosolic linker protein, was not affected. These results indicate down-regulation 
of adherens- and tight junctions, resulting in a loosening of the HUVEC mono-
layer, a sign of proinflammatory activation. Increased endothelial permeability is a 
mechanism required for both leukocyte extravasation and angiogenesis, and both 
phenomena are required in wound repair.
VEGF is also produced in nemosis, as shown in this study (III), in line with an-
other publication from our group (Räsänen et al., 2008). Even if VEGF has been 
characterized as a master regulator of angiogenesis, it was first identified as a vas-
cular permeability factor (Senger et al., 1983). Intracellular signaling through VEGF 
association with VEGFR2 has been shown to induce tyrosine phosphorylation on 
VE-cadherin in an in vivo-model of VEGF-dependent angiogenesis (Lambeng et al., 
2005), suggesting that the VEGF stimulus causes reduced permeability of the en-
dothelium. The study by Lambeng et al., along with another study by Gavard and 
Gutkind (Gavard and Gutkind, 2006) proposes that VEGF-stimulation activates VE-
cadherin internalization by way of Src, resulting in VE-cadherin phosphorylation, 
subsequent recruitment of β-arrestin2, and receptor internalization. Microvascular 
integrity is also maintained by the promotion of new integrin connections through 
the connection of VEGFR2 and Src by VE-cadherin. This mechanism plays a role in 
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fluid shear stress mechanosensing of endothelial cells (Tzima et al., 2005). Because 
fibroblasts in nemosis produce VEGF and modulate endothelial VE-cadherin (II, III), 
the aforementioned cooperative interactions of VEGF and VE-cadherin may also 
regulate the endothelial permeability-modulating response of nemosis. Fibroblasts 
in nemosis also produce PGE2, a molecule known for its leakage-inducing proper-
ties (Crunkhorn and Willis, 1971). COX-2 and its product PGE2 are upregulated by 
fibronectin (Han et al., 2004), which in turn has a crucial influence on the onset of 
nemotic activation of fibroblasts (Salmenperä et al., 2008). 
A recent hypothesis suggests that vascular inflammation can also take place as 
a result of outside-in signaling originating from the microenvironment, where ac-
tivated, proinflammatory fibroblasts and leukocytes agitate the endothelium and 
thus indirectly also circulatory leukocytes (Maiellaro and Taylor, 2007). Such regu-
latory behavior of the surrounding tissue may have implications in cardiovascular 
disease.
In this study, the experiments on endothelial activation have been conducted 
using human umbilical vein endothelial cells (II, III). It can be argued that differ-
ences exist between arterial and venous endothelial cells (Sato, 2003; Wang et 
al., 1998) and that the physiological location for most inflammatory endothelial 
activation and leukocyte transmigration is the post-capillary venule (Granger and 
Kubes, 1994). Nonetheless, HUVECs have been shown to work remarkably well as 
an in vitro model for such functions, as most surface markers have been initially 
discovered in HUVECs and later confirmed in vivo, at a physiologically relevant 
location (Zimmerman et al., 1999). Yet, the extent of HUVEC resemblance to mi-
crovascular cells and the tissue-specific heterogeneity of endothelial cells can be 
debated. Certainly, differences do exist, for example in the expression of chemokine 
receptors (Gerber et al., 2009), but because many inflammatory activation-specif-
ic markers are present in both microvascular and macrovenous endothelial cells, it 
would seem probable that HUVECs perform decently as an easily handled, general 
in vitro endothelial cell model.
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Fibroblast nemosis has angiogenesis-promoting properties (III)
Wound repair requires a complex scaffold or microenvironment, consisting of 
several cell types, ECM structures, and signaling processes that aid in the recon-
struction of the tissue. Angiogenesis is an important part of the formation of such a 
scaffold, and the vascular-forming response of endothelial cells is regulated by the 
tissue microenvironment (Langenkamp and Molema, 2009).
Nemotic fibroblasts promote angiogenic properties of endothelial cells
Previous work by our group revealed that nemotic fibroblasts are a source of 
proangiogenic growth factors such as HGF and VEGF (Kankuri et al., 2005; Räsänen 
et al., 2008), leading us to further investigate the potential proangiogenic role of 
nemosis. In this study we show that nemotic fibroblasts produce elevated levels of 
VEGF. Even if the increase in secreted VEGF is a moderate 2-fold, it contributes to 
the promotion of endothelial cell (HUVEC) sprouting and networking on basement 
membrane matrix, as shown by the effect of inhibitory antibodies against VEGF in 
conditioned nemotic fibroblast medium, as presented below. 
Fibroblasts undergoing nemosis are known to secrete abundant amounts of 
HGF of which at least 50% is in its active form (Kankuri et al., 2005). In this study 
we investigated the response of endothelial cells plated on basement membrane 
matrix after treating them with nemotic fibroblast or monolayer medium. The re-
sults show that HGF secreted into the medium also plays a role in the promotion 
of endothelial cell sprouting, as well as networking of the sprouts, together with 
VEGF. Inhibition of both HGF and VEGF by antibodies led to a maximal decrease 
of 39% in sprout number and 51% in the number of branching points, whereas 
sprout length remained unaffected. However, a combination of both function-in-
hibiting antibodies did not result in a significantly enhanced inhibition of endothe-
lial sprouting. This unexpected result could potentially be due to a convergence of 
downstream signaling routes, resulting in a maximum inhibition of sprouting when 
either HGF or VEGF is separately blocked.
In this study we also investigated the effect of nemotic fibroblasts on human 
endothelial cells in a classical scratch-wound repair assay. Conditioned medium 
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induced significantly faster closure of both microvascular (HMEC-dNeo) and um-
bilical venous (HUVEC) endothelial monolayer scratch-wounds at 24 hours than 
medium from fibroblast monolayer cultures. The process was partly dependent 
on HGF, which inhibited closure up to 56%. VEGF, on the other hand, was not in-
volved. Furthermore, we investigated whether this response was due to increased 
proliferation or migration of the endothelial cells. No signs of an induced prolif-
eratory response could be detected, but we observed a moderate but statistically 
significant increase in the migration of single endothelial cells at the edges of the 
scratch-wound. Since HGF, like many other growth factors, acts as an endothe-
lial cell motogen (Bussolino et al., 1992), its effect may be sufficient to close the 
wound. Interestingly, even if VEGF is known to induce endothelial cell proliferation, 
VEGF-containing nemotic fibroblast medium does not seem to promote prolifera-
tion of endothelial cells in vitro. 
Fibroblasts undergoing nemosis secrete an assortment of angiogenesis-inducing 
signaling molecules. Blocking one or two such molecules is evidently not sufficient 
to abolish angiogenic responses in endothelial cells. Yet, since a major source of HGF 
and VEGF in healing wounds is the activated fibroblast, the significant inhibitory ef-
fects establish the importance of these factors in the angiogenesis-promoting role 
of nemosis. The HGF receptor MET, mostly expressed by epithelial and endothelial 
cells, can be activated by IL-1 and IL-6 (Moghul et al., 1994). These cytokines are 
also produced by fibroblasts in nemosis (Kankuri et al., 2008), suggesting a possible 
proactive manipulation of the HGF signal received by endothelial cells. Neutrophils 
are also known to be activated upon HGF stimulation, and they also are capable 
of storing abundant amounts of HGF (Jiang et al., 1992; Mine et al., 1998). It has 
therefore been suggested that ECM-bound and neutrophil-derived HGF provides 
the early source of HGF in tissue, whereas fibroblasts, once activated, are respon-
sible for the sustained release of HGF. Interestingly, VEGF has been shown to in-
duce CXCL12 (stromal cell-derived growth factor-1; SDF-1) in perivascular myofi-
broblasts, which in turn homes bone marrow-derived mononuclear myeloid cells 
to perivascular tissue, where they show a proangiogenic phenotype (Grunewald 
et al., 2006). Since stromal fibroblasts and inflammatory cells are both important 
sources of VEGF, it is appealing to think of activated fibroblasts as signal amplifiers, 
by both secreting VEGF and CXCL12, possibly by a feed-back loop. This in turn leads 
to the accumulation of monocytes and to further inflammatory progression.
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Other angiogenesis-promoting factors involved in nemosis
The expression of the proangiogenic chemokine CXCL8 has been found to be 
elevated in acute wounds (Engelhardt et al., 1998). The results presented here 
show that high levels of expressed and secreted CXCL8 is produced by nemotic 
fibroblasts, which suggests that the proangiogenic response of fibroblast nemo-
sis may contain additional factors. Besides direct induction of angiogenesis, VEGF 
and HGF have been shown to further advance angiogenesis by activating signaling 
pathways in several cell types that contribute to the expression of CXCL8 (Dong et 
al., 2001; Nor et al., 2001), which could possibly also implicate a self-amplifying 
loop in nemotic fibroblasts.
This study, along with other observations, concludes that COX-2 is robustly in-
duced in the nemosis response of many types of fibroblast strains, together with 
the secretion of prostaglandins (Bizik et al., 2004; Räsänen et al., 2009). Expression 
of COX-2 has been linked to chronic inflammation and angiogenesis (Chang et al., 
2004; Wang et al., 2005) and its upregulation is known to be associated with HGF-
promoted angiogenesis (Boccaccio et al., 2005). This could have implications for 
nemosis-driven angiogenic responses. COX-2 and VEGF are known to be induced 
by hypoxia (Chida and Voelkel, 1996; Tuder et al., 1995), but we have been un-
able to find conditions of oxidative stress in nemotic fibroblasts. COX-2 is induced 
throughout the spheroid, and we have been unable to detect a necrotic or hypoxic 
center (Bizik et al., 2004). Therefore, we assume that the induction of VEGF, as well 
as other growth factors and cytokines produced, is also an intrinsic property of the 
nemosis process.
Recently, the importance of NF-κB in angiogenesis has been recognized. This 
transcription factor functions as a hub, controlling the transcription of a plethora of 
cellular response elements, including several crucial for angiogenesis, such as VEGF 
(Kiriakidis et al., 2003; Tabruyn and Griffioen, 2008). Some angiogenic factors such 
as HGF are capable of activating NF-κB (Fan et al., 2005). Nemotic fibroblasts har-
bor activated NF-κB, and they also and secrete abundant amounts of HGF, which 
could imply NF-κB-driven responses and feed-back loops, as well as have implica-
tions for the angiogenesis-promoting effect of nemosis.
The production of fibronectin has been shown to be of importance in the early 
stages of nemosis, where it initiates cluster formation (Salmenperä et al., 2008). 
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Fibronectin also promotes endothelial cell adhesion, growth, and survival, as well 
as ECM-deposited HGF and VEGF activity (Rahman et al., 2005; Sottile, 2004; Wi-
jelath et al., 2002). For new vasculature to form, space must be made by breaking 
down the ECM by proteolytic means. Fibroblasts are a major source of cellular fi-
bronectin, and nemotic fibroblasts additionally secrete MMPs (Siren et al., 2006), 
providing a potential mechanism by which fibroblasts could aid angiogenesis indi-
rectly (Hughes, 2008). 
This study demonstrates how nemotic fibroblasts influence the localization of 
the tight junction component claudin-5, the adherens junction component VE-cad-
herin, and the tight- and adherens junction adapter component ZO-1 in endothe-
lial cell monolayers, causing them to be down-regulated at intercellular junctions. 
Vascular permeability is linked to neovascularization, and VE-cadherin is known to 
be of importance in angiogenesis by repressing endothelial proliferation, maintain-
ing survival, and in such a manner stabilizing the vessel structure (Carmeliet et al., 
1999; Caveda et al., 1996). Loosening of endothelial cell-cell contacts is required 
for sprouting and migration, the initial events performed by endothelial cells com-
mitted to angiogenesis, and newly formed vessels are leaky until properly stabilized 
(Adams and Alitalo, 2007). 
The dark side: inflammation-related damage and tumorigenesis 
Inflammation has evolved to act as a driving force for wound repair in postnatal 
tissues. However, the inflammatory process can also be harmful. When a wound 
repair process fails to switch off the inflammatory phase, acute inflammation turns 
into chronic inflammation. Functionally altered fibroblasts are found in the stroma 
of chronically inflamed wounds, such as venous ulcers (Harding et al., 2005). Fi-
broblasts are also abundant in scarring tissue (Desmouliere et al., 2005), as well 
as in interstitial fibrosis of the lung (Mornex et al., 1994) and kidney (González-
Cuadrado et al., 1996), conditions which impair tissue and organ functionality. In 
fact, hypertrophic scarring seems to be an overreaction of stromal myofibroblasts 
(Desmouliere et al., 2005). Fibroblasts are also commonly present in granulomas, 
which have been described as cytokine factories (Mornex et al., 1994; Powell et 
al., 1999). A common factor in all these pathological conditions is the presence of 
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chronic inflammation, which drives the activation of fibroblasts. Fibroblasts attract 
leukocytes, and together these two cell types make up the main components of 
inflammatory stroma. Especially macrophages are known to be recruited by fibro-
blasts, and they further boost fibroblast immunoactivation, proliferation, and ECM 
production by additional chemokine production (Mrowietz et al., 1999). Such feed-
back and cross-talk between cells in the stroma establishes a vicious cycle that 
augments the inflammatory response.
Interestingly, inflammation is not a prerequisite for successful wound repair. 
Some early fetal tissues such as skin heal in a regenerative manner, since the acute 
immune response, and subsequently inflammation, are almost completely absent 
(Yannas et al., 2007). Such healing is scarless and includes perfect regeneration 
of the tissue surrounding the wound, including glands and hair follicles. It would 
seem that immune cells such as neutrophils and macrophages are not required 
for successful wound repair in a situation where infection is not a danger (Wilgus 
2008). Fibroblasts are present in fetal wounds, but the matrix composition is dif-
ferent (Yannas et al., 2007) and the number of myofibroblasts is low (Estes et al., 
1994). Bearing in mind that scar-forming repair has de facto evolved as the repair 
process of choice in post-natal mammals, consideration of the balance of positive 
and negative aspects in the wound healing process provides an interesting perspec-
tive on evolutionary advantages. 
In recent years it has become evident that chronic inflammation and inflamma-
tion-related responses are implicated in the initiation and progress of many types 
of cancer (Mantovani et al., 2008; Schafer and Werner, 2008). Chronic inflamma-
tion has also been shown to increase the risk of cancer at the site of inflammation 
(O’Byrne and Dalgleish, 2001). Classical examples are H. pylori-induced gastritis 
and gastric cancer, hepatitis B and C infection and liver cancer (Castello et al., 2010; 
Chemin and Zoulim, 2009), as well as inflammatory bowel disease and colorectal 
cancer (Balkwill et al., 2005). 
Solid tumors are surrounded by stroma, a scaffolding structure with resemblance 
to the inflammatory microenvironment found at sites of acute inflammation. A 
growth-supporting stroma seems to be an essential requirement for an advancing 
tumor (Mueller and Fusenig, 2002). Some types of cancer, such as scirrhous-type 
gastric carcinoma, are associated with extensive fibrosis and an abundance of fi-
broblasts (Semba et al., 2009). Fibroblasts found in the tumor stroma are in many 
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ways similar to inflammation-associated fibroblasts: they produce cytokines and 
growth factors required for tumor progression, whereas fibroblasts from normal, 
healthy tissue have been shown to suppress tumor progression (Olumi et al., 1999; 
Orimo and Weinberg, 2006; Pierce et al., 1982). These so-called cancer-associat-
ed fibroblasts (CAFs) have been shown to remain constantly activated, and often 
display markers of the myofibroblastic phenotype (De Wever et al., 2008; Hinz, 
2007b; Kalluri and Zeisberg, 2006; Östman and Augsten, 2009). CAFs seem to be 
able to drive tumorigenesis starting from an early, hyperplasic stage, and continu-
ing all the way through different stages of malignancy (Erez et al., 2010). Because 
of their important role in supporting the initiation and progression of cancer, CAFs 
are considered a possible therapeutic target (Kalluri and Zeisberg, 2006; Micke and 
Östman, 2004).
Several factors produced by stromal fibroblasts also play roles in tumor progres-
sion. Activated fibroblasts attract leukocytes and support their maintenance, which 
has been suggested to indirectly aid tumorigenesis (Buckley et al., 2001). A certain 
subtype of macrophages has in particular been implicated in tumorigenesis (Silzle 
et al., 2003; Solinas et al., 2009). Chemokines, such as CXCL8 and CXCL5, are ca-
pable of promoting tumor cell proliferation (Põld et al., 2004), whereas CCL5 is 
implicated in tumor progression and metastasis-formation (Mrowietz et al., 1999). 
Cross-talk between malignant cells and fibroblasts seems to further stimulate tu-
mor progression, illustrated by a study where melanoma cell lines stimulated the 
secretion of, among others, IL-6, CXCL8, and MCP-1 in fibroblasts, which then re-
sponded by increasing the invasive potential of the melanoma cells (Li et al., 2009). 
Glu-Leu-Arg-positive CXCL chemokines are also known to promote angiogenesis, 
with implications for tumor vascularization (Gerber et al., 2009; Keeley et al., 2008; 
Strieter et al., 1995). 
The cytokine regulator NF-κB seems to be of crucial importance in many kinds 
of cancer, as it promotes the production of pro-tumorigenic cytokines and prevents 
apoptosis. These attributes make NF-κB a link between inflammation and cancer 
by producing proinflammatory agents, as well as by protecting cells with malignant 
potential from death (Greten et al., 2004; Karin, 2006).
As rapidly growing structures, developing tumors require the infusion of nutri-
tion and depend on neovascularization for development beyond a critical volume 
(Folkman et al., 1971). For historical reasons, many important discoveries in the 
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study of neovascularization have been made in a tumor environment. Tumor vas-
cularization also provides a way for malignant cells to escape into the circulatory 
system, thus allowing metastasis. In contrast to fibroblasts isolated from normal 
tissue, CAFs originating from invasive breast carcinoma promote tumor vascular-
ization (Orimo et al., 2005), and they have also found to be associated with mi-
crovascular proliferation (Zeine et al., 2009). CAFs vascularize an in vivo basement 
membrane plug more efficiently than fibroblasts from normal tissue, even without 
the presence of malignant cells (Erez et al., 2010). Effective vascularization of the 
tumor often correlates with poor prognosis. 
HGF has been linked to angiogenesis (Bussolino et al., 1992). High levels of the 
HGF receptor MET have been reported in many carcinomas, and such abundant 
expression seems to be essential for growth and survival of tumors (Shinomiya et 
al., 2004). Both HGF and MET are implicated in many types of cancer, and over-
expression of either one results in tumorigenesis and aggressive metastasis (Birch-
meier et al., 2003; Rong et al., 1994). VEGF, an important proangiogenic factor, 
was originally discovered in the context of cancer (Folkman et al., 1971). In tumors, 
the main source of VEGF is stromal inflammatory cells and fibroblasts (Fukumura 
et al., 1998). HGF and VEGF are known to cooperate by upregulating proinflam-
matory and angiogenic factors, as well as by promoting angiogenic responses of 
endothelial cells in a synergistic manner (Gerritsen et al., 2003; Wojta et al., 1999). 
Malignant keratinocytes seem to boost the HGF and VEGF produced by nemotic fi-
broblasts (Räsänen et al., 2008), suggesting enhanced growth factor production in 
a tumor environment. Since nemotic fibroblasts promote angiogenic responses in 
endothelial cells, the proangiogenic effect of nemotic fibroblasts may be enhanced 
by tumor cells.
In conclusion, fibroblasts in the tumor stroma are an important part of the 
microenvironment that supports growth and progression of malignant tissue. Fi-
broblasts undergoing nemosis display a variety of traits common to fibroblasts 
found in tumor stroma, such as the secretion of proteolytic enzymes, prostaglan-
dins, growth factors, and cytokines. Recent research by Erez et al. has identified a 
proinflammatory gene signature, consisting of, among other, CXCL1, CXCL2, IL-6, 
COX-2, and NF-κB, in CAFs from various stages of dermal HPV-induced mouse skin 
carcinoma and human squamous cell carcinoma (Erez et al., 2010). All these mark-
ers are upregulated in nemosis. Similarities between inflammation- and cancer-
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associated fibroblasts suggest that nemosis could be a model for not only inflam-
mation- but cancer-associated stromal activation, as well.
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Concluding remarks
Activation of fibroblasts in the stroma of inflammatory tissue is an essential 
mechanism for promoting repair of damaged tissue. Related activation mechanisms 
have been found in the stroma of tumors. This study, along with other work by our 
group, has characterized clustering-induced fibroblast activation, or nemosis, and 
allowed us to link it with phenomena such as inflammation and tumorigenesis. We 
have illustrated a variety of responses and traits in nemosis that resemble those 
of stromal fibroblasts in inflammation, including cancer-associated inflammatory 
conditions (Figure 4).
Promotion of tumorigenesis
(HGF, VEGF, MMP-10,
MMP-14, PGs, plasminogen
activation)
Promotion of inflammation
(MIP-1α, RANTES, IL-1β, IL-6,
IL-8, PGs)
Promotion of inflammation
and angiogenesis
(HGF, VEGF, IL-8, PGs)
Promotion of
nemosis
Promotion of
proliferation (HGF)
Inhibition of
nemosis
Tumor cells
Endothelial cells
Nemotic fibroblast
cluster
Epithelial cells
Inflammatory cells
Figure 4. Schematic model of signals produced by nemotic fibroblasts and possible paracrine 
cross-talk within the inflammation- and tumor microenvironment. Adapted from publication 
IV (Vaheri et al., 2009).
 Currently, nemosis is an in vitro model that provides a way to investigate 
stromal activation in a controlled laboratory environment. The flexibility, versa-
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tility, and in-depth observation provided by in vitro studies is essential in under-
standing the mechanisms and potential impacts of nemosis. This study contributes 
to the foundation of research from which physiological and pathological implica-
tions can be derived, predicted, and understood. Clues for possible in vivo relevance 
scetch a picture of the inflammatory site, where an abundance of fibroblasts is 
often found. We may find the physiological counterpart of nemosis in interactions 
between these fibroblasts to be a mechanism for immunoactive awakening, in line 
with the sentinel cell theory of fibroblasts as an extension of the immunosurveil-
lance system. In vitro, necrosis-like cell death occurs in the spheroid. However, in 
vivo the situation may be different and cell death may be delayed or lacking, due to 
intercellular signaling routes at the site of inflammation, prolonging the proinflam-
matory response of the fibroblast.
In our model, proximity between fibroblasts is key to the activation process. 
Whether direct contacts without intervening ECM molecules are required for nem-
otic activation is as yet unclear. We know that fibronectin, an ECM protein produced 
by fibroblasts in abundance, plays an important role as a mediator for nemotic ac-
tivation (Salmenperä et al., 2008), and that fibroblasts, specifically myofibroblasts, 
are known to make direct contacts in healing wound environments (Gabbiani et al., 
1978). Connexin-43 is expressed in nemotic fibroblasts, but we have been unable 
to detect functional gap junctions between cells (our unpublished observations). 
Further work is required to elucidate how the nemosis model translates to a physi-
ological situation, and whether it has an actual counterpart in tissue or if it is rather 
a convenient model to study stromal activation. Nemotic fibroblasts and myofi-
broblasts also share characteristics, but further profiling is required to determine 
a possible relationship between the two. Currently, in vivo detection of nemosis 
is complicated by the heterogeneity of fibroblasts and the lack of a precise tissue 
marker, as well as limitations in distinguishing actual cluster- or proximity-induced 
activation of fibroblasts in tissue.
Most of our work has been conducted on primary human foreskin fibroblasts, 
in line with its potential relevance to skin wounds. In this study we have also ex-
amined other strains of human fibroblasts of skin and lung origin, both adult and 
embryonic, with the conclusion that these also show nemotic morphology, up-
regulation of COX-2, and secretion of CXCL8 (publication I; supplemental data). 
Notably, another study by our group compared paired strains of normal and can-
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cer-associated fibroblasts and concluded that some variation in the nemosis re-
sponse of fibroblasts does exist (Räsänen et al., 2009). This observation, along with 
unpublished observations on epithelial and endothelial cells that do not undergo 
nemosis, points to a conclusion that the general characteristics of nemotic behav-
ior seem to be an intrinsic property of fibroblasts.
Anchorage-dependent cells, such as epithelial and endothelial cells, are known 
to react to loss of growth support by losing their sense of polarity, resulting in an 
apoptotic form of cell death termed “anoikis”. Caspase activation and induction of 
apoptosis-related genes such as Fas and Baxx are key regulators of the anoikis path-
way (Chiarugi and Giannoni, 2008). However, previous studies on nemosis have 
seen no upregulation of caspases or apoptosis-related proteins (Bizik et al., 2004). 
In the present study we also compared spheroid formation of HUVECs and HMEC-
dNeo endothelial cells to fibroblasts, noting a rapid morphological decomposition 
and no induction of COX-2 (publication III, supplemental data), as expected of a 
cell type known to undergo anoikis in suspension conditions. We also seeded fibro-
blasts on flat-bottom, agarose-coated plates at low numbers and observed a spon-
taneous clustering of the cells, making a direct comparison of anoikis and nemosis 
of fibroblasts impossible (our unpublished results). Based on the results above we 
conclude that nemosis of fibroblasts is a pathway different from anoikis.
The production of cytokines is strongly augmented in fibroblasts undergo-
ing nemosis. So far we have not detected anti-inflammatory cytokines, and the 
chemokines produced include ones with both proinflammatory and proangiogenic 
effects. In addition, nemotic fibroblasts are also a rich source of growth factors, 
some with angiogenic properties, especially HGF and VEGF. Inducing nemosis in 
primary fibroblasts can be considered a means of directing inflammation and in-
ducing angiogenesis, thus promoting a wound healing response and subsequent 
tissue regeneration in a controlled fashion. 
In conclusion, nemosis can be seen as an in vitro model that facilitates care-
ful examination of the activation process of stromal fibroblasts, or it can actually 
reflect a mechanism for such activation in vivo. Most importantly, regardless of 
whether nemosis is found in physiological surroundings, it may hold therapeutic 
potential in situations where a wound healing- or tissue regeneration response is 
either desired in a controlled fashion or must be suppressed. 
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